Summit Therapeutics Inc. Common Stock
Here’s whether Summit Therapeutics Inc. Common Stock (SMMT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.65% over 10 days); weak 1-year return of -30.5%; 3-month momentum negative (-13.4%); rising volume on a downtrend (distribution, 1.42x avg). Currently 54.8% off its 52-week high. Score: -6/7.
SMMT is trading below its 200-day MA ($18.16) — a key warning sign the longer-term trend is under pressure. An RSI of 31.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -30.5% compares to +22.9% for SPY (trailed the market by 53.4%). The current 54.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.